Sanofi is not the only drugmaker divesting its generics, UK group Shire also announced in April 2018 the sale of its oncology business to unlisted French drugmaker Servier for US$2.4 billion.

The sale is part of Sanofi’s plan to simplify and reshape the company and shift the company towards businesses with more potential for growth. Sanofi has been taking ‘a series of strategic steps’ in recent months that, as well as selling certain products, include buying biotechnology company Ablynx and US haemophilia specialist Bioverativ for US$16 billion. These acquisitions, according to Sanofi, will establish the company ‘as a new global leader in rare blood disorders’, as well as provide the company with ‘the powerful new Nanobody technology platform’.

Advent and Sanofi expect the deal to close by the end of 2018.

Related articles
Strategic biologicals alliance between Sanofi and JHL Biotech in China

Sanofi fined for discouraging generic clopidogrel prescriptions

Sanofi starts biosimilar insulin trials

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2018 Pro Pharma Communications International. All Rights Reserved.